ELVN · Categories · Form 4

ELVN - SEC Form 4 insider transactions

Enliven Therapeutics Inc. (ELVN) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for ELVN

• 5d
  SEC Form 4 filed by Collins Helen Louise

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 30d
  SEC Form 4 filed by Collins Helen Louise

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 38d
  SEC Form 4 filed by Collins Helen Louise

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 46d
  SEC Form 4 filed by Enliven Therapeutics Inc.

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 47d
  CHIEF FINANCIAL OFFICER Hohl Benjamin sold $295,839 worth of shares (10,000 units at $29.58), decreasing direct ownership by 16% to 51,000 units (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 66d
  Director Heyman Richard A. sold $32,196 worth of shares (1,230 units at $26.18) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 66d
  CHIEF MEDICAL OFFICER Collins Helen Louise exercised 45,000 shares at a strike of $2.48 and sold $1,177,862 worth of shares (45,000 units at $26.17) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 68d
  SEC Form 4 filed by Director Kunkel Lori Anne

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 68d
  SEC Form 4 filed by Director Heyman Richard A.

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 68d
  SEC Form 4 filed by Director Gupta Rishi

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 68d
  SEC Form 4 filed by Director Garland J. Scott

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 68d
  SEC Form 4 filed by Director Derynck Mika K

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 68d
  SEC Form 4 filed by Director Bauer Jake

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 68d
  SEC Form 4 filed by Director Ballal Rahul D.

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 68d
  CHIEF OPERATING OFFICER Patel Anish was granted 20,000 shares (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 68d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P was granted 18,750 shares (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 68d
  CHIEF FINANCIAL OFFICER Hohl Benjamin was granted 25,000 shares, increasing direct ownership by 69% to 61,000 units (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 68d
  CHIEF MEDICAL OFFICER Collins Helen Louise was granted 25,000 shares (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 75d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $145,219 worth of shares (5,000 units at $29.04) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 94d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $535,099 worth of shares (20,000 units at $26.75) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 94d
  Director Heyman Richard A. sold $32,902 worth of shares (1,230 units at $26.75) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 103d
  CHIEF OPERATING OFFICER Patel Anish sold $1,351,762 worth of shares (48,300 units at $27.99) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 104d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $3,476,014 worth of shares (132,500 units at $26.23) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 104d
  Director Heyman Richard A. sold $348,281 worth of shares (13,920 units at $25.02) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 107d
  SEC Form 4 filed by Director Garland J. Scott

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 124d
  CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 13,000 shares at a strike of $2.48, increasing direct ownership by 57% to 36,000 units (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 124d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $84,206 worth of shares (5,000 units at $16.84) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 128d
  Director Kunkel Lori Anne exercised 15,958 shares at a strike of $1.12, increasing direct ownership by 108% to 30,712 units (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 135d
  SEC Form 4 filed by PRESIDENT AND CEO Fair Richard A.

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 137d
  CHIEF OPERATING OFFICER Patel Anish sold $140,073 worth of shares (6,663 units at $21.02) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 156d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $279,155 worth of shares (12,500 units at $22.33) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 158d
  PRESIDENT AND CEO Kintz Samuel sold $272,739 worth of shares (12,500 units at $21.82) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 165d
  CHIEF OPERATING OFFICER Patel Anish sold $116,034 worth of shares (6,667 units at $17.40) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 186d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $276,025 worth of shares (12,500 units at $22.08) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 187d
  PRESIDENT AND CEO Kintz Samuel sold $266,654 worth of shares (12,500 units at $21.33) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 199d
  CHIEF OPERATING OFFICER Patel Anish sold $133,993 worth of shares (6,667 units at $20.10) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 207d
  CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,250 shares at a strike of $2.48 and sold $66,291 worth of shares (3,250 units at $20.40) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 208d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $81,005 worth of shares (4,000 units at $20.25) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 208d
  PRESIDENT AND CEO Kintz Samuel sold $74,228 worth of shares (3,700 units at $20.06) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 213d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $30,045 worth of shares (1,500 units at $20.03) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 213d
  PRESIDENT AND CEO Kintz Samuel sold $56,084 worth of shares (2,800 units at $20.03) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 215d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $135,697 worth of shares (7,000 units at $19.39) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 219d
  PRESIDENT AND CEO Kintz Samuel sold $115,723 worth of shares (6,000 units at $19.29) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 228d
  CHIEF OPERATING OFFICER Patel Anish sold $134,957 worth of shares (6,667 units at $20.24) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 240d
  CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,250 shares at a strike of $2.48 and sold $67,039 worth of shares (3,250 units at $20.63) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 248d
  Amendment: PRESIDENT AND CEO Kintz Samuel sold $30,343 worth of shares (1,517 units at $20.00) (SEC Form 4)

  4/A - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 248d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $248,216 worth of shares (12,500 units at $19.86) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 249d
  PRESIDENT AND CEO Kintz Samuel sold $219,906 worth of shares (10,983 units at $20.02) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 258d
  CHIEF OPERATING OFFICER Patel Anish sold $121,616 worth of shares (6,667 units at $18.24) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 270d
  CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,250 shares at a strike of $2.48 and sold $66,504 worth of shares (3,250 units at $20.46) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 277d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $278,646 worth of shares (12,500 units at $22.29) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 279d
  PRESIDENT AND CEO Kintz Samuel sold $281,518 worth of shares (12,500 units at $22.52) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 286d
  CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 1,000 shares at a strike of $2.48 and sold $22,655 worth of shares (1,000 units at $22.66) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 291d
  CHIEF OPERATING OFFICER Patel Anish sold $131,951 worth of shares (6,667 units at $19.79) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 299d
  CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,250 shares at a strike of $2.48 and sold $67,956 worth of shares (3,250 units at $20.91) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 306d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $267,458 worth of shares (12,500 units at $21.40) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 312d
  PRESIDENT AND CEO Kintz Samuel sold $277,292 worth of shares (12,500 units at $22.18) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 313d
  CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,000 shares at a strike of $2.48 and sold $67,655 worth of shares (3,000 units at $22.55) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 319d
  CHIEF OPERATING OFFICER Patel Anish sold $135,574 worth of shares (6,667 units at $20.34) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 325d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $150,220 worth of shares (7,500 units at $20.03) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

Other ELVN categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends